Severity of pain on day 3 · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes severity of pain on day 3 compared with standard treatment alone (very low certainty).
1 finding from 1 review
Duration of time requiring intravenous antibiotics · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes duration of time requiring intravenous antibiotics compared with standard treatment alone (very low certainty).
1 finding from 1 review
Surgical intervention · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes need for surgical intervention compared with standard treatment alone (very low certainty).
1 finding from 1 review
Adverse effects: exposure keratopathy · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes adverse effects: exposure keratopathy compared with standard treatment alone (very low certainty).
1 finding from 1 review
Return visit to health care (not reported) · patients age 10 years and older with periorbital or orbital cellulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CRM197‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
CRM197‐PCV7in high‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
OMPC‐PCV7in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV10in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
PHiD‐CV11in low‐risk infants · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
1 finding from 1 review
Adverse effects · infants (predominantly < 6 months of age) and older children (aged 1 to 7 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
All‐cause mortality · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes mortality compared with rituximab (very low certainty).
1 finding from 1 review